CR20200642A - Proteínas inmunodominantes y fragmentos en esclerosis múltiples - Google Patents

Proteínas inmunodominantes y fragmentos en esclerosis múltiples

Info

Publication number
CR20200642A
CR20200642A CR20200642A CR20200642A CR20200642A CR 20200642 A CR20200642 A CR 20200642A CR 20200642 A CR20200642 A CR 20200642A CR 20200642 A CR20200642 A CR 20200642A CR 20200642 A CR20200642 A CR 20200642A
Authority
CR
Costa Rica
Prior art keywords
multiple sclerosis
fragments
immunodominant proteins
immunodominant
proteins
Prior art date
Application number
CR20200642A
Other languages
English (en)
Inventor
Ramos Mireia Sospedra
Roland Martin
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Publication of CR20200642A publication Critical patent/CR20200642A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01271—GDP-L-fucose synthase (1.1.1.271)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/904—Oxidoreductases (1.) acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)

Abstract

<p>La descripción se refiere al tratamiento, diagnóstico y/o prevención de esclerosis múltiple (MS) al utilizar una proteína o péptido inmunodominante. De manera más particular la invención se refiere al campo de inmunoterapias específicas de antígeno, tal como la inducción de tolerancia.</p>
CR20200642A 2018-06-28 2019-06-28 Proteínas inmunodominantes y fragmentos en esclerosis múltiples CR20200642A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18180326.3A EP3586866A1 (en) 2018-06-28 2018-06-28 Immunodominant proteins and fragments in multiple sclerosis
PCT/EP2019/067468 WO2020002674A1 (en) 2018-06-28 2019-06-28 Immunodominant proteins and fragments in multiple sclerosis

Publications (1)

Publication Number Publication Date
CR20200642A true CR20200642A (es) 2021-04-28

Family

ID=62814962

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200642A CR20200642A (es) 2018-06-28 2019-06-28 Proteínas inmunodominantes y fragmentos en esclerosis múltiples

Country Status (20)

Country Link
US (1) US20210162019A1 (es)
EP (2) EP3586866A1 (es)
JP (2) JP2021528965A (es)
KR (1) KR20210041559A (es)
CN (1) CN112512554A (es)
AU (1) AU2019294465A1 (es)
BR (1) BR112020026458A2 (es)
CA (1) CA3104231A1 (es)
CL (1) CL2020003355A1 (es)
CO (1) CO2020016105A2 (es)
CR (1) CR20200642A (es)
EC (1) ECSP20083339A (es)
IL (1) IL279608A (es)
JO (1) JOP20200329A1 (es)
MX (1) MX2020014003A (es)
PE (1) PE20211739A1 (es)
PH (1) PH12020552222A1 (es)
SG (1) SG11202012661WA (es)
WO (1) WO2020002674A1 (es)
ZA (1) ZA202007822B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112710843B (zh) * 2020-12-16 2022-11-04 江苏伟禾生物科技有限公司 一种测定群体反应性抗体检测的板式免疫荧光试剂盒及其制备方法
EP4119948A1 (en) * 2021-07-16 2023-01-18 Universität Zürich Method for stratification and treatment of multiple sclerosis
WO2023285617A1 (en) * 2021-07-16 2023-01-19 Universität Zürich Method for stratification and treatment of multiple sclerosis
WO2024094562A1 (en) 2022-11-01 2024-05-10 Universität Zürich Novel mbp peptides and their use in the treatment of multiple sclerosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932443A (en) * 1997-09-26 1999-08-03 Incyte Pharmaceuticals, Inc. Human antigens
JP2001145488A (ja) * 1999-11-19 2001-05-29 Natl Inst Of Advanced Industrial Science & Technology Meti シロイヌナズナ由来のｇｄｐ−４−ケト−６−デオキシ−ｄ−マンノース−３，５−エピメラーゼ−４−レダクターゼ遺伝子
JP2006141297A (ja) * 2004-11-19 2006-06-08 Eiken Chem Co Ltd 血管新生を検出するためのマーカー
JP2009505631A (ja) * 2005-07-28 2009-02-12 オンコセラピー・サイエンス株式会社 癌関連遺伝子ｒａｓｇｅｆ１ａ
EP2057998A1 (en) 2007-10-31 2009-05-13 Universitätsklinikum Hamburg-Eppendorf Use of modified cells for the treatment of multiple sclerosis
EP2437060A1 (de) * 2010-10-01 2012-04-04 Protagen AG Markersequenzen für Multiple Sklerose und deren Verwendung
DE102010042359A1 (de) * 2010-10-12 2012-04-12 Protagen Ag Markersequenzen für Multiple Sklerose und deren Verwendung
WO2014059052A1 (en) * 2012-10-09 2014-04-17 Uab Research Foundation Methods and compositions for diagnosis and treatment of parkinson's disease and parkinsonism
EP3043647A4 (en) * 2013-09-12 2017-05-10 Teva Pharmaceutical Industries Ltd. Gene expression biomarkers of laquinimod responsiveness
CN107502615B (zh) * 2017-10-16 2020-05-05 中国海洋大学 海带中编码gdp-甘露糖-4,6-脱水酶的基因、及其蛋白质和用途

Also Published As

Publication number Publication date
SG11202012661WA (en) 2021-01-28
AU2019294465A1 (en) 2021-01-14
US20210162019A1 (en) 2021-06-03
ZA202007822B (en) 2021-10-27
ECSP20083339A (es) 2021-03-31
WO2020002674A1 (en) 2020-01-02
EP3586866A1 (en) 2020-01-01
BR112020026458A2 (pt) 2021-05-25
IL279608A (en) 2021-03-01
JOP20200329A1 (ar) 2019-06-28
CO2020016105A2 (es) 2021-03-19
CA3104231A1 (en) 2020-01-02
JP2021528965A (ja) 2021-10-28
PH12020552222A1 (en) 2021-06-28
JP2024116146A (ja) 2024-08-27
CL2020003355A1 (es) 2021-07-23
PE20211739A1 (es) 2021-09-06
CN112512554A (zh) 2021-03-16
EP3813865A1 (en) 2021-05-05
MX2020014003A (es) 2021-03-25
KR20210041559A (ko) 2021-04-15

Similar Documents

Publication Publication Date Title
CR20200642A (es) Proteínas inmunodominantes y fragmentos en esclerosis múltiples
MX2022013526A (es) Degradadores de proteinas y usos de los mismos.
MX2021001098A (es) Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares.
MX2024002706A (es) Proteinas de union a antigeno del virus del papiloma anti-humano (vph) y metodos de uso de las mismas.
MX2017004007A (es) Modulacion de celulas mieloides estimulantes y no estimulantes.
WO2018187356A3 (en) Protein antigens and uses thereof
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
PH12017502020A1 (en) Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
GB201206070D0 (en) Clostridium difficile antigens
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
MX2021007589A (es) Anticuerpos anti il-36 y procedimientos de uso de estos.
PH12020552270A1 (en) Anti-steap1 antigen-binding protein
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
ZA202110285B (en) Antibodies and methods of use
MX2018000023A (es) Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina.
MX2021015766A (es) Nuevos antigenos y metodos contra el cancer.
MX2018011193A (es) Proteinas derivadas de alfa-1-microglobulina novedosas y su uso.
MX2022000263A (es) Nuevos antigenos y metodos contra el cancer.
MX2021015765A (es) Nuevos antigenos y metodos contra el cancer.
MX2021004453A (es) Nuevos antigenos y metodos contra el cancer.
MX2022003523A (es) Proteinas de union a antigenos.
EP4155734A3 (en) Method
EA202092204A1 (ru) Композиции